Clinical Trials for Bladder Cancer

A Phase 1/2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressing or recurrent small cell lung cancer, pulmonary large-cell neuroendocrine carcinoma, or extrapulmonary neuroendocrine carcinoma after prior systemic therapy (or when standard second-line therapy is unsuitable) receive [203Pb]Pb-MP0712 imaging followed by [212Pb]Pb-MP0712, a DLL3-binding DARPin that delivers alpha radiation to tumors. DLL3-positive imaging is required for extrapulmonary disease and for lung tumors in dose expansion.

ClinicalTrials.gov ID: NCT07278479

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.

ClinicalTrials.gov ID: NCT07186842

A Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLT012 in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors, excluding primary CNS malignancies, and ECOG performance status 0–1 receive intravenous PLT012 every 3 weeks in a single-arm dose-escalation study. PLT012 is an investigational antibody that blocks the lipid-binding region of CD36, a protein involved in lipid uptake.

ClinicalTrials.gov ID: NCT07337525

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: For patients with unresectable locally advanced or metastatic urothelial carcinoma who have received no prior systemic therapy for advanced disease, this single-arm study adds MK-3120 to first-line enfortumab vedotin plus pembrolizumab. MK-3120 is an investigational Nectin-4–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT07232602

A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced breast, non-small cell lung, gastric/GEJ, or bladder cancer lacking a suitable standard treatment undergo [68Ga]Ga-DWJ155 PET imaging; those eligible then receive intravenous [177Lu]Lu-DWJ155. This investigational HER2-targeted radioligand delivers localized beta radiation to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT07660055

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic antigen-rich solid tumors and no more than three prior lines of therapy for advanced disease receive intravenous STAR0602 (invikafusp alfa) monotherapy. This investigational antibody–cytokine fusion targets T-cell receptor Vβ6/Vβ10 subsets and stimulates the IL-2 receptor to expand potentially tumor-reactive T cells.

ClinicalTrials.gov ID: NCT05592626

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.

ClinicalTrials.gov ID: NCT03556228